Coherus BioSciences Inc. (CHRS), a biopharmaceutical company focused on immunotherapies for cancer, announced on Wednesday that it will present final clinical and biomarker data from its phase II study of Casdozokitug in combination with Atezolizumab and Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma next month.
Interim results from the study, as of the data cutoff on November 9, 2023, and reported in January, demonstrated a 38% objective response rate, which included three complete responses. Furthermore, more than 60% of patients exhibited tumor shrinkage on their initial scans.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.